Cytostatic effect of the hypothalamic cytokine prp-1 is mediated by mTOR and cMYc inhibition in high grade chondrosarcoma

Neurochemical Research

Volumn 36, Issue 5, 2011, Pages 812-818

  Galoian, Karina ^a   Temple, Thomas H ^a   Galoyan, Armen ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b H Buniatian Institute of Biochemistry National Academy of Sciences of Armenia   (Armenia)

Author keywords

Cell cycle; Chondrosarcoma; cMyc; Hypothalamus; mTOR; Primary cultures; Proline rich polypeptide 1

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PROLINE RICH PROTEIN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CELL CYCLE PROGRESSION; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CHONDROSARCOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; HUMAN; HUMAN CELL; HYPOTHALAMUS; IMMUNOPRECIPITATION; INHIBITION KINETICS; MICROSCOPY; MOLECULAR MECHANICS; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CHONDROSARCOMA; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPOTHALAMUS; PEPTIDES; PROTO-ONCOGENE PROTEINS C-MYC; TOR SERINE-THREONINE KINASES;

MAMMALIA;

EID: 79954428164     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-011-0406-5     Document Type: Article

References (31)

1. Galoyan AA (2004) Brain neurosecretory cytokines: immune response and neuronal survival. Kluwer Academic/Plenum Publishers, NY
2. Galoyan A (2008) In: Lajtha A (ed) Handbook of neurochemistry and neurobiology, vol: neuroimmunology (Galoyan A, Besedovsky H (eds)). Springer, New York, pp 155-196
3. AA Galoyan SL Grigorian CV Badalyan 2006 Treatment and prophylaxis of anthrax by brain neurosecretory cytokines Neurochem Res 31 6 795 803 16804761 10.1007/s11064-006-9082-2 1:CAS:528:DC%2BD28Xnt1aitLs%3D (Pubitemid 44114813)
4. AA Galoyan JS Sarkissian VA Chavushyan, et al. 2005 Neuroprotective action of hypothalamic peptide PRP-1 at various time survival following spinal cord hemisection Neurochem Res 30 4 507 525 16076021 10.1007/s11064-005-2686-0 1:CAS:528:DC%2BD2MXlvVemuro%3D (Pubitemid 40933659)
5. AA Galoyan 2000 Neurochemistry of brain neuroendocrine immune system: signal molecules Neurochem Res 25 9/10 1343 1355 11059805 10.1023/A: 1007656431612 1:CAS:528:DC%2BD3cXns1eitbo%3D
6. AA Galoyan VS Aprikyan 2002 A new hypothalamic polypeptide is a regulator of myelopoiesis Neurochem Res 27 4 305 312 11958532 10.1023/A:1014959212651 1:CAS:528:DC%2BD3sXjsFGi (Pubitemid 34273572)
7. AA Galoyan VA Shakhlamov LI Kondakova VI Altukhova GP Polyakova 2001 The influence of proline-rich polypeptide on the morphology and mitotic activity of neurinoma Hassel node of tumor cells at rats (electron microscopic investigations) PNAS (Russian Academy of Sciences) 101 2 279 286
8. 929 under PRP effect in vitro Med Sci Armenia 41 1 25 29
9. AA Galoyan KS Margaryan GG Hovhannisyan GH GasparyanD N Aroutiounian RM Aroutiounian 2009 Study of the genotoxic effects of a Proline-RichPolypeptide using the comet assay Neurochem J 3 2 145 148 10.1134/S1819712409020111
10. RM Aroutiounian GG Hovhannisyan GH Gasparyan KS Margaryan DN Aroutiounian NK Sarkissyan AA Galoyan 2010 Proline-rich polypeptide-1 protects the cells in vitro from genotoxic effects of mitomycin C Neurochem Res 35 4 598 6022 19949858 10.1007/s11064-009-0104-8 1:CAS:528:DC%2BD1MXhsV2mu7%2FJ
11. RK Chailakhyan YV Gerasimov MR Chailakhyan AA Galoyan 2010 Proline- rich hypothalamic polypeptide has opposite effects on the proliferation of human normal bone marrow stromal cells and human giant-cell tumour stromal cells Neurochem Res 35 6 934 939 20087764 10.1007/s11064-009-0113-7 1:CAS:528:DC%2BC3cXotFSrsQ%3D%3D
12. K Galoian S Scully G McNamara P Flynn A Galoyan 2009 Antitumorigenic effect of brain proline rich polypeptide-1 in human chondrosarcoma Neurochem Res 34 12 2117 2121 10.1007/s11064-009-0009-6 1:CAS:528:DC%2BD1MXms1aktLw%3D
13. K Galoian S Scully A Galoyan 2009 Myc-oncogene inactivating effect by proline rich polypeptide (PRP-1) in chondrosarcoma JJ012 cells Neurochem Res 34 2 379 385 18612811 10.1007/s11064-008-9794-6 1:CAS:528:DC%2BD1MXpvFWluw%3D%3D
14. Schantz JT (2009) Manual in biomedical research, v (Manual for Primary Human Cell cultures. World Scientific Publishing Co Pte Ltd
15. Freshney R (1987) Culture of animal cells: a manual of basic technique (1987) Alan R. Liss, Inc
16. WG Kaelin Jr CB Thompson 2010 Clues from cell metabolism Nature 465 3 562 564 20520704 10.1038/465562a 1:CAS:528:DC%2BC3cXmvFWktr4%3D
17. C Barrios JS Castresana A Kreicbergs 1994 Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification Am J Clin Oncol 17 273 276 8192117 10.1097/00000421-199406000- 00019 1:STN:280:DyaK2c3kvFKntw%3D%3D (Pubitemid 24160623)
18. C Morrison M Radmacher N Mohammed D Susterm H Auer S Jones J Riggenbach N Kelbick G Bos J Mayerson 2005 MYC amplification and polysomy 8 in chondrosarcoma: array comparative genopmic hybridization, fluorescent in situ hybridization, and association with outcome J Clin Oncol 23 36 9369 9376 16361637 10.1200/JCO.2005.03.7127 1:CAS:528:DC%2BD28Xnt1ymsA%3D%3D
19. Heiko Hermeking 2003 The Myc oncogene as a cancer drug target Curr Cancer Drug Targets 3 163 175 12769686 10.2174/1568009033481949 1:CAS:528: DC%2BD3sXjvVekt7c%3D (Pubitemid 36565759)
20. DW Felsher Nicole Bradon 2003 Pharmacological Inactivation of MYC for the treatment of cancer Drug News Perspect 16 6 370 374 12973448 10.1358/dnp.2003.16.6.829309 1:CAS:528:DC%2BD3sXosFyrs7c%3D (Pubitemid 37221190)
21. EM Berns JG Klijn WL van Putten IL van Staveren H Portengen JA Foekens 1992 c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer Cancer Res 52 1107 1113 1737370 1:STN:280:DyaK387ksFKmtQ%3D%3D
22. RJ Shaw 2006 Glucose metabolism and cancer Curr Opin Cell Biol 18 6 598 608 17046224 10.1016/j.ceb.2006.10.005 1:CAS:528:DC%2BD28XhtF2qtbjI (Pubitemid 44692479)
23. IB Rosenwald R Kaspar D Rousseau L Gehrke P Leboulch JJ Chen EV Schmidt N Sonenberg IM London 1995 Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels J Biol Chem 270 36 21176 21180 7673150 10.1074/jbc.270.36.21176 1:CAS:528:DyaK2MXnvFKls7c%3D
24. CJ Nelsen DG Rickheim MM Tucker LK Hansen JH Albrecht 2003 Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes J Biol Chem 278 6 3656 3663 12446670 10.1074/jbc.M209374200 1:CAS:528:DC%2BD3sXot1Kkuw%3D%3D (Pubitemid 36801089)
25. 4E inhibitory proteins Nature 433 477 480 15690031 10.1038/nature03205 1:CAS:528:DC%2BD2MXpt1Cnug%3D%3D (Pubitemid 40204297)
26. EV Schmidt 2004 The role of c-myc in regulation of translation initiation Oncogene 23 3217 3221 15094771 10.1038/sj.onc.1207548 1:CAS:528: DC%2BD2cXjtFOmsbk%3D (Pubitemid 38638833)
27. BM Curtis MB Widmer P de Roos EE Qwarnstrom 1990 IL-1 and its receptor are translocated to the nucleus J Immunol 144 4 1295 1303 2137488 1:CAS:528:DyaK3cXhsFKns7Y%3D (Pubitemid 20072898)
28. PS Subramaniam MM Green J Larkin III BA Torres HM Johnson 2001 Nuclear Translocation of IFN-g Is an intrinsic requirement for its biologic activity and can be driven by a heterologous nuclear localization sequence J Interferon Cytokine Res 21 951 959 11747627 10.1089/107999001753289569 1:CAS:528: DC%2BD3MXptFOitb0%3D (Pubitemid 34048720)
29. EL Korn SG Arbuck JM Pluda R Simon RS Kaplan MC Christian 2001 Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 19 1 265 272 11134222 1:CAS:528:DC%2BD3MXot1Wnsw%3D%3D (Pubitemid 32063505)
30. E Pasquier M Carré B Pourroy L Camoin O Rebaï C Briand D Braguer 2004 Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway Mol Cancer Ther 3 10 1301 1310 15486197 1:CAS:528:DC%2BD2cXosVSrsL4%3D (Pubitemid 39440174)
31. LK Edward GA Susan MP James S Richard SK Richard CC Michaele 2001 Clinical trial designs for cytostatic agents: are new approaches needed J Clin Oncol 19 1 265 272